TGTX
TG Therapeutics Inc
55.80$
-0.7%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -23,008.1% | -29,328.0% | -40,419.3% | -61,532.3% | -84,819.1% | -87,372.4% | -141,123.0% | -4,419.7% | -6,325.7% | -13.4% | -12.3% | -4.0% | |
| 2.6% | 10.1% | 41.3% | 54.0% | 57.9% | 185.5% | 246.1% | 7.4% | 18.5% | 0.2% | 0.1% | 0.0% | |
| 13,850.3% | 10,301.2% | 4,928.4% | 10,464.1% | 8,477.6% | 7,457.2% | 52,821.7% | 916.0% | 688.9% | 16.2% | 12.9% | 10.5% | |
| 13,926.0% | 10,264.0% | 4,834.8% | 10,502.6% | 8,437.5% | 7,538.8% | 53,313.8% | 907.4% | 684.7% | – | – | – | |
| -3,968.2% | 1,356.1% | 5,756.5% | 5,620.6% | 18,265.1% | 16,572.4% | -12,998.0% | -182.6% | -59.1% | -36.2% | -33.2% | -31.6% | |
| 12.2% | 27.7% | 225.7% | 1.5% | 59.2% | 86.2% | 234.9% | 6.0% | 0.5% | 0.0% | 0.0% | 0.0% | |
| -12,045.7% | -16,200.1% | 17,420.4% | -5,386.8% | 776.3% | -472.4% | -16,125.0% | -5.0% | -718.6% | -21.7% | -0.3% | 2.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 0.0% | 0.0% | 0.0% | – | – | – | – | |
| 45,526.2% | 45,168.3% | 3,300.6% | 87,713.4% | 74,762.5% | 115,145.4% | 447,254.6% | 36.4% | 21.0% | 0.0% | -2.7% | -14.8% | |
| -478.9% | -68.4% | -8.9% | 19,679.0% | 19,728.3% | 19,205.3% | 26,315.8% | 582.8% | -35.0% | 10.7% | 41.7% | 0.0% | |
| 45,047.3% | 45,099.9% | 3,291.7% | 87,713.4% | 74,762.5% | 134,350.7% | 447,254.6% | 619.2% | -14.0% | 31.1% | 39.1% | -14.6% | |
| 9,993.6% | -428.2% | -19,707.2% | 20,794.3% | -9,280.3% | 46,505.9% | 290,006.6% | -3,805.5% | -7,058.3% | -4.0% | 26.4% | -16.3% | |
| -23,020.3% | -29,355.7% | -40,645.0% | -61,533.8% | -84,878.3% | -87,458.6% | -141,357.9% | -4,425.7% | -6,326.2% | -13.4% | -12.3% | -4.1% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.